Retour

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Stocks Earnings Releases and Operating Results

- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities -

GlobeNewswire Inc. • 09/05/2024 à 13:30:00
Sensei Biotherapeutics, Inc. Common Stock
Address: 1405 RESEARCH BLVD, SUITE 125
Postal Code: 20850
City: ROCKVILLE
State: MD
Phone Number: (240) 243-8000
Website: https://www.senseibio.com
Status: Active
Company Info

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.

List Date2021-02-04
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001829802
Composite figiBBG00V3M3TP5
Share Class figiBBG00V3M3TR3
Market Cap38,373,866 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees28
Share Class Shares Outstanding25080000
Weighted Shares Outstanding25080958
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
1.544
1.595
1.576
1.539
1.66
Variance
-3.14%
1.27%
4.37%
-7.62%
12.54%
Open
1.594
1.575
1.51
1.666
1.475
Highest
1.645
1.665
1.594
1.694
1.808
Lowest
1.645
1.665
1.576
1.691
1.736
History
PeriodVarhighestlowest
1 week
4.68%
1.808
1.576
1 month
52.12%
1.03
1.026
3 month
94.7%
0.822
0.777
6 month
94.7%
0.822
0.777
1 year
94.7%
0.822
0.777
3 year
94.7%
0.822
0.777
5 year
94.7%
0.822
0.777
10 year
94.7%
0.822
0.777
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-03 2023-11-07 UNPUB
Assets 107,933,000 89,580,000 81,658,000 UNPUB
Current Assets 98,608,000 81,069,000 73,836,000 UNPUB
Current Liabilities 7,583,000 5,357,000 6,226,000 UNPUB
Equity 94,850,000 79,201,000 71,000,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 94,850,000 79,201,000 71,000,000 UNPUB
Liabilities 13,083,000 10,379,000 10,658,000 UNPUB
Liabilities And Equity 107,933,000 89,580,000 81,658,000 UNPUB
Noncurrent Assets 9,325,000 8,511,000 7,822,000 UNPUB
Noncurrent Liabilities 5,500,000 5,022,000 4,432,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-03 2023-11-07 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -9,686,000 2,117,000 1,117,000 UNPUB
Net Cash Flow, Continuing -9,686,000 2,117,000 1,117,000 UNPUB
Net Cash Flow From Financing Activities -262,000 -7,946,000 -2,534,000 UNPUB
Net Cash Flow From Financing Activities, Continuing -262,000 -7,946,000 -2,534,000 UNPUB
Net Cash Flow From Investing Activities 2,312,000 19,526,000 8,312,000 UNPUB
Net Cash Flow From Investing Activities, Continuing 2,312,000 19,526,000 8,312,000 UNPUB
Net Cash Flow From Operating Activities -11,736,000 -9,463,000 -4,661,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -11,736,000 -9,463,000 -4,661,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-03 2023-11-07 UNPUB
Comprehensive Income/Loss -9,996,000 -9,112,000 -6,977,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -9,996,000 -9,112,000 -6,977,000 UNPUB
Other Comprehensive Income/Loss 181,000 274,000 147,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-03 2023-11-07 UNPUB
Basic Earnings Per Share 0 0 0 UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share 0 0 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -10,177,000 -9,386,000 -7,124,000 UNPUB
Income/Loss From Continuing Operations Before Tax -10,177,000 -9,386,000 -7,124,000 UNPUB
Income Tax Expense/Benefit 0 0 0 UNPUB
Interest Expense, Operating 42,000 38,000 33,000 UNPUB
Net Income/Loss -10,177,000 -9,386,000 -7,124,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -10,177,000 -9,386,000 -7,124,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -10,177,000 -9,386,000 -7,124,000 UNPUB
Operating Expenses 11,008,000 10,177,000 7,737,000 UNPUB
Operating Income/Loss -11,008,000 -10,177,000 -7,737,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 0 0 0 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 UNPUB 2022-11-08 2023-03-29
Assets 150,038,000 UNPUB 128,803,000 118,375,000
Current Assets 138,977,000 UNPUB 118,482,000 108,589,000
Current Liabilities 7,606,000 UNPUB 8,492,000 9,066,000
Equity 135,308,000 UNPUB 113,986,000 103,407,000
Equity Attributable To Noncontrolling Interest 0 UNPUB 0 0
Equity Attributable To Parent 135,308,000 UNPUB 113,986,000 103,407,000
Liabilities 14,730,000 UNPUB 14,817,000 14,968,000
Liabilities And Equity 150,038,000 UNPUB 128,803,000 118,375,000
Noncurrent Assets 11,061,000 UNPUB 10,321,000 9,786,000
Noncurrent Liabilities 0 UNPUB 6,325,000 5,902,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 UNPUB 2022-11-08 2023-03-29
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 1,562,000 UNPUB UNPUB 10,636,000
Net Cash Flow, Continuing 1,562,000 UNPUB UNPUB 10,636,000
Net Cash Flow From Financing Activities 119,000 UNPUB UNPUB -287,000
Net Cash Flow From Financing Activities, Continuing 119,000 UNPUB UNPUB -287,000
Net Cash Flow From Investing Activities 12,193,000 UNPUB UNPUB 49,949,000
Net Cash Flow From Investing Activities, Continuing 12,193,000 UNPUB UNPUB 49,949,000
Net Cash Flow From Operating Activities -10,750,000 UNPUB UNPUB -39,026,000
Net Cash Flow From Operating Activities, Continuing -10,750,000 UNPUB UNPUB -39,026,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 UNPUB 2022-11-08 2023-03-29
Comprehensive Income/Loss -12,405,000 UNPUB -13,409,000 -49,259,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 UNPUB 0 0
Comprehensive Income/Loss Attributable To Parent -12,971,000 UNPUB -13,409,000 -49,259,000
Other Comprehensive Income/Loss -566,000 UNPUB 7,000 -671,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 UNPUB 2022-11-08 2023-03-29
Basic Earnings Per Share UNPUB UNPUB 0 -2
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB 0 -2
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -12,405,000 UNPUB -13,416,000 -48,588,000
Income/Loss From Continuing Operations Before Tax -12,405,000 UNPUB -13,416,000 -56,632,000
Income Tax Expense/Benefit 0 UNPUB UNPUB -8,044,000
Interest Expense, Operating 243,000 UNPUB 10,000 219,000
Net Income/Loss -12,405,000 UNPUB -13,416,000 -48,588,000
Net Income/Loss Attributable To Noncontrolling Interest 0 UNPUB 0 0
Net Income/Loss Attributable To Parent -12,405,000 UNPUB -13,416,000 -48,588,000
Net Income/Loss Available To Common Stockholders, Basic -12,405,000 UNPUB -13,416,000 -48,588,000
Operating Expenses 12,487,000 UNPUB 13,941,000 50,188,000
Operating Income/Loss -12,487,000 UNPUB -13,941,000 -50,188,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 UNPUB 0 0
Preferred Stock Dividends And Other Adjustments 0 UNPUB 0 0
Revenues 0 UNPUB 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-13 2021-08-11 2021-11-10 2022-03-15
Assets 174,476,000 167,724,000 161,249,000 153,225,000
Current Assets 172,785,000 165,613,000 158,162,000 148,542,000
Current Liabilities 2,475,000 3,923,000 5,264,000 4,889,000
Equity 171,252,000 163,125,000 155,208,000 146,513,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 171,252,000 163,125,000 155,208,000 146,513,000
Liabilities 3,224,000 4,599,000 6,041,000 6,712,000
Liabilities And Equity 174,476,000 167,724,000 161,249,000 153,225,000
Noncurrent Assets 1,691,000 2,111,000 3,087,000 4,683,000
Noncurrent Liabilities 0 0 777,000 1,823,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-13 2021-08-11 2021-11-10 2022-03-15
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 152,822,000 -153,819,000 -6,066,000 -9,437,000
Net Cash Flow, Continuing 152,822,000 -153,819,000 -6,066,000 -9,437,000
Net Cash Flow From Financing Activities 164,076,000 -11,000 -7,000 163,940,000
Net Cash Flow From Financing Activities, Continuing 164,076,000 -11,000 -7,000 163,940,000
Net Cash Flow From Investing Activities -487,000 -147,761,000 -482,000 -143,118,000
Net Cash Flow From Investing Activities, Continuing -487,000 -147,761,000 -482,000 -143,118,000
Net Cash Flow From Operating Activities -10,767,000 -6,047,000 -5,577,000 -30,259,000
Net Cash Flow From Operating Activities, Continuing -10,767,000 -6,047,000 -5,577,000 -30,259,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-13 2021-08-11 2021-11-10 2022-03-15
Comprehensive Income/Loss -7,972,000 -9,771,000 -9,653,000 -37,127,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -7,972,000 -9,872,000 -9,653,000 -37,127,000
Other Comprehensive Income/Loss 0 -101,000 32,000 -333,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-13 2021-08-11 2021-11-10 2022-03-15
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -7,972,000 -9,771,000 -9,685,000 -36,794,000
Income/Loss From Continuing Operations Before Tax -7,972,000 -9,771,000 -9,685,000 -45,097,000
Income Tax Expense/Benefit 0 0 0 -8,303,000
Interest Expense, Operating 3,000 147,000 214,000 670,000
Net Income/Loss -7,972,000 -9,771,000 -9,685,000 -36,794,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -7,972,000 -9,771,000 -9,685,000 -36,794,000
Net Income/Loss Available To Common Stockholders, Basic -7,972,000 -9,771,000 -9,685,000 -36,794,000
Operating Expenses 7,969,000 9,784,000 10,316,000 37,482,000
Operating Income/Loss -7,969,000 -9,784,000 -10,316,000 -37,482,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Calendar
20 May 2024 (Time UTC) Actual Previous Consensus
★
10:30
United States
★★
09:00
United States
★★
09:00
United States
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-5400.000
-17800.000
★
15:30
United States
-66000.000
-60000.000
★
15:30
United States
59500.000
53700.000
★
15:30
United States
-116600.000
-135800.000
★★
15:30
United States
3200.000
4400.000
★
15:30
United States
203000.000
215400.000
★
15:30
United States
200.000
-31400.000
★
15:30
United States
61800.000
62600.000
★
15:30
United States
1300.000
1300.000
★
15:30
United States
-25300.000
-9700.000
★
15:30
United States
204500.000
199600.000
News Stream
Stocks Earnings Releases and Operating Results
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities -
GlobeNewswire Inc. • 1w ago
Health Health
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), will be presented in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024.
GlobeNewswire Inc. • 3w ago
Calendar Calendar of Events
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
BOSTON, April 09, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a panel titled ‘KRAS and VISTA - Better Approaches for Key Targets’ at Canaccord Genuity’s Horizons in Oncology Virtual Conference on Monday, April 15th at 2:00 p.m. ET.
GlobeNewswire Inc. • 1mo ago
News Product / Services Announcement
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment
BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the publication of a peer-reviewed research paper in Nature Communications. The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine.
GlobeNewswire Inc. • 1mo ago
Calendar Calendar of Events
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate on a panel titled ‘Anti-VISTA Immunotherapies in Clinical Development’ at the 3rd Annual VISTA Symposium. The VISTA Symposium will convene scientific experts and industry leaders to explore the important emerging role of VISTA in cancer immunotherapy and will review the latest insights on VISTA biology, the growing potential of VISTA as a therapeutic target in multiple cancer indications and share updates on the ongoing clinical development of anti-VISTA therapies. The symposium will take place virtually on Wednesday, March 27 from 11 a.m. to 3:30 p.m. ET.
GlobeNewswire Inc. • 1mo ago
Calendar Calendar of Events
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that the company will present preclinical data on its conditionally active immuno-oncology programs at upcoming scientific conferences.
GlobeNewswire Inc. • 2mo ago
News Conference Calls/ Webcasts
Sensei Biotherapeutics to Present at Upcoming Conferences
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in February 2024:
GlobeNewswire Inc. • 3mo ago
Stocks Corporate Action
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
- Completed SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities -
GlobeNewswire Inc. • 4mo ago
Stocks Annual Meetings & Shareholder Rights
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
- Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encouraging cytokine release profile across multiple dose cohorts -
GlobeNewswire Inc. • 6mo ago
Management Directors and Officers
Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.
GlobeNewswire Inc. • 6mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT